Ikeda S - Search Results

1

Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma.

Ikeda S, Tsigelny IF, Skjevik ÅA, Kono Y, Mendler M, Kuo A, Sicklick JK, Heestand G, Banks KC, Talasaz A, Lanman RB, Lippman S, Kurzrock R. Ikeda S, et al. Oncologist. 2018 May;23(5):586-593. doi: 10.1634/theoncologist.2017-0479. Epub 2018 Feb 27. Oncologist. 2018. PMID: 29487225 Free PMC article.

2

Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma.

Ikeda S, Hansel DE, Kurzrock R. Ikeda S, et al. Cancer Treat Rev. 2015 Sep;41(8):699-706. doi: 10.1016/j.ctrv.2015.06.004. Epub 2015 Jun 23. Cancer Treat Rev. 2015. PMID: 26138514 Free article. Review.

3

Molecular landscape of prostate cancer: implications for current clinical trials.

Khemlina G, Ikeda S, Kurzrock R. Khemlina G, et al. Among authors: ikeda s. Cancer Treat Rev. 2015 Nov;41(9):761-6. doi: 10.1016/j.ctrv.2015.07.001. Epub 2015 Jul 9. Cancer Treat Rev. 2015. PMID: 26210103 Free article. Review.

4

Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors.

Millis SZ, Ikeda S, Reddy S, Gatalica Z, Kurzrock R. Millis SZ, et al. Among authors: ikeda s. JAMA Oncol. 2016 Dec 1;2(12):1565-1573. doi: 10.1001/jamaoncol.2016.0891. JAMA Oncol. 2016. PMID: 27388585

5

Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.

Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL. Singh AR, et al. Among authors: ikeda s. Mol Cancer Ther. 2016 Nov;15(11):2553-2562. doi: 10.1158/1535-7163.MCT-15-0976. Epub 2016 Aug 5. Mol Cancer Ther. 2016. PMID: 27496136 Free PMC article.

6

Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy.

Ikeda S, Goodman AM, Cohen PR, Jensen TJ, Ellison CK, Frampton G, Miller V, Patel SP, Kurzrock R. Ikeda S, et al. NPJ Genom Med. 2016;1:16037-. doi: 10.1038/npjgenmed.2016.37. Epub 2016 Oct 19. NPJ Genom Med. 2016. PMID: 27942391 Free PMC article.

7

JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease.

Patel M, Ikeda S, Pilat SR, Kurzrock R. Patel M, et al. Among authors: ikeda s. JAMA Dermatol. 2017 May 1;153(5):449-452. doi: 10.1001/jamadermatol.2016.5554. JAMA Dermatol. 2017. PMID: 28241173 Free PMC article.

8

Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease.

Cohen PR, Kato S, Goodman AM, Ikeda S, Kurzrock R. Cohen PR, et al. Among authors: ikeda s. Int J Mol Sci. 2017 Jul 31;18(8):1663. doi: 10.3390/ijms18081663. Int J Mol Sci. 2017. PMID: 28788102 Free PMC article.

9

Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing.

Schwaederle M, Chattopadhyay R, Kato S, Fanta PT, Banks KC, Choi IS, Piccioni DE, Ikeda S, Talasaz A, Lanman RB, Bazhenova L, Kurzrock R. Schwaederle M, et al. Among authors: ikeda s. Cancer Res. 2017 Oct 1;77(19):5419-5427. doi: 10.1158/0008-5472.CAN-17-0885. Epub 2017 Aug 14. Cancer Res. 2017. PMID: 28807936 Free PMC article.

10

The biology of Hepatocellular carcinoma: implications for genomic and immune therapies.

Khemlina G, Ikeda S, Kurzrock R. Khemlina G, et al. Among authors: ikeda s. Mol Cancer. 2017 Aug 30;16(1):149. doi: 10.1186/s12943-017-0712-x. Mol Cancer. 2017. PMID: 28854942 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,552 results

Search Page

Filters